Clinical and Microbiological Aspects of Probiotics in Non-surgical Periodontal Therapy.
NCT ID: NCT06063226
Last Updated: 2023-10-04
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
70 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-10-01
Study Completion Date
2024-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this randomized clinical trial is to test the effect orally administration of Probiotics based on Lactobacillus rhamnosus LR04 and Lactobacillus plantarum LP14 as adjuvant in people suffering from periodontitis stage II-III. The main questions it aims to answer are:
* QUESTION 1: orally administered probiotics based on the previous strains could represent a useful tool in support of non-surgical periodontal therapy in reducing clinical periodontal indexes?
* QUESTION 2: orally administered probiotics based on the previous strains could represent a useful tool in support of non-surgical periodontal therapy in reduce the amount of periodontal pathogens in periodontal pockets?
Partecipants in the test group will take the test probiotic for 90 days in adjunction of the routinary oral hygiene procedures.
Partecipants in the positive controlled group will take the placebo for 90 days in adjunction of the routinary oral hygiene procedures.
Partecipants in the negative control group will perform only the routinary oral hygiene procedures.
Researchers will compare 3 groups to see if orally administered probiotics based on L. rhamnosus and L. plantarum may hel in the reduction of periodontal indexes and of the periodontal pathogen bacteria.
* QUESTION 1: orally administered probiotics based on the previous strains could represent a useful tool in support of non-surgical periodontal therapy in reducing clinical periodontal indexes?
* QUESTION 2: orally administered probiotics based on the previous strains could represent a useful tool in support of non-surgical periodontal therapy in reduce the amount of periodontal pathogens in periodontal pockets?
Partecipants in the test group will take the test probiotic for 90 days in adjunction of the routinary oral hygiene procedures.
Partecipants in the positive controlled group will take the placebo for 90 days in adjunction of the routinary oral hygiene procedures.
Partecipants in the negative control group will perform only the routinary oral hygiene procedures.
Researchers will compare 3 groups to see if orally administered probiotics based on L. rhamnosus and L. plantarum may hel in the reduction of periodontal indexes and of the periodontal pathogen bacteria.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lactobacillus Reuteri in the Supportive Therapy of Periodontitis
NCT04478643
Periodontal Diseases
COMPLETED
NA
Efficacy of Oral Probiotic and Antibiotic Administration in Patients With Chronic Periodontitis
NCT02839408
Chronic Periodontitis
UNKNOWN
PHASE2
Efficacy of Oral Probiotic Administration in Patients With Chronic Periodontitis
NCT02283736
-Chronic Periodontitis
UNKNOWN
PHASE2
Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy
NCT07029360
Pregnancy
Periodontal Disease
Gingivitis
+4 more
RECRUITING
NA
Antibiotic and Probiotic Therapies in the Adjuvant Treatment of the Chronic Periodontitis.
NCT03692819
Chronic Periodontitis Complex
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The diagnosis of periodontitis passes through the recording of periodontal probing values on 6 sites for each periodontal element, the recording of clinical indices such as the percentage of bleeding sites and those with plaque, finally through the execution of a full-x-ray consisting of intraoral films that guarantee staging through the calculation of the loss of clinical attachment, corresponding to the loss of alveolar bone caused by the disease. The therapy of periodontitis is composed of several steps and begins with the control of the biofilm. This control is carried out with professional supragingival hygiene sessions followed by subgingival instrumentation of the periodontal pockets in order to remove the hard and soft deposits below the gingival margin, which would not otherwise be eliminated with the supragingival strategy alone. The response to mechanical therapy and the risk of relapses go hand in hand with the patient's response, his ability to maintain a good level of oral hygiene at home and to keep return appointments. In this sense, dental research has worked hard to develop additional aids to mechanical therapy to try to improve its performance. In the last decade in particular, the use of probiotics has found an increasingly wider field in periodontology, as they are based on the idea of enhancing the eubiosis ratios of the non-pathogenic flora in order to make the environment unfavorable for the proliferation of a pathogenic flora.
The present study aims to evaluate whether the quarterly oral administration of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 can improve the response to non-surgical periodontal therapy of subgingival instrumentation in patients suffering from stage II-III periodontitis and complexity of grade A-B.
Primary objective To evaluate the adjuvant effect of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 in non-surgical periodontal therapy.
Secondary objective Characterize the microbiological picture of patients with periodontitis with and without the aid of probiotics.
MATERIALS AND METHODS Three groups of volunteers of both sexes will be enrolled for the study without age restrictions.
Inclusion criteria Patients in the absence of other systemic pathologies reported in the medical history, smokers and non-smokers, non-drinkers, in the absence of previous or current administration of other sources of probiotics, capable of providing informed consent.
Exclusion criteria Subjects with a history of systemic diseases (diabetes, autoimmune diseases, inflammatory bowel diseases, neurodegenerative diseases), drinkers, who take or have taken probiotics in the last 3 months, unable to provide informed consent.
Minimum sample size Sample size calculation (Alpha = 0.05; Power = 95%) for 3 independent study groups, and a continuous primary endpoint. Sample size = Z2 (1-alpha/2) p (1-p) / d2 Where Z(1-alpha/2) is the standard variate corresponding to 1.96 at 5% type 1 error, p is the expected proportion in the population expressed in decimals based on previous studies and d is the confidence level decided by the researcher expressed in decimal. Regarding the primary outcome of Bleeding On Probing (BOP), the expected difference between the means was assumed to be 20%, therefore 20 patients per group are required, for a total of 60 patients. To these patients, the dropout percentage of 10% must be added, so the total is 70 patients.
T0 - BASELINE The first dental visit and the treatment plan will be carried out by Prof. Marco Dolci. The periodontal visit with the registration of the indices and the full-rx will be carried out by Prof. Marco Dolci.
Clinical indixes
* Bleeding On Probing - BOP, percentage value on 6 sites for each tooth
* Pocket Probing Depth - PPD on 6 sites for each tooth
* Clinical Attachment Loss - CAL on intraoral radiographs of pathological sites
* Plaque Index - PI, rated from 0 to 4 for each site
* Percentage of pathological sites out of total sites. The recording of BOP, PPD, PI will be carried out through periodontal probing using the PCP-15 UNC periodontal probe (HuFriedi) in a completely atraumatic and non-invasive manner.
The operational session will be organized as follows:
* Supragingival instrumentation with piezoelectric ultrasonic scaler handpiece;
* BPA microbiological test (Bacterial Periodontal Assessment - Biomolecular Diagnostic, Via Nicola Porpora, 550144 - Florence) through sampling of the gingival crevicular fluid with a thin cone of sterile paper with a diameter of 0.3 mm positioned in the pocket for 60 seconds, in an atraumatic and non-traumatic manner invasive. After sampling, the cones will be inserted into a single test tube;
* Subgingival instrumentation of periodontal pockets using Gracey curettes. The treatment is to be considered as Full Mouth Treatment (FMT). The samples will be transported to the laboratory located on the third floor of Building A, taken into custody by Prof. Marco Dolci and stored at + 4° C until the arrival of the dedicated courier.
The same Biomolecular Diagnostic company will take care of collecting the samples via dedicated biological courier and will carry out the PCR analyzes in its laboratories.
At the end of the analyses, a copy of a unique identification code will be sent to the Experimenters so that they can access the report.
Placement of the patient in the test, positive and negative control groups
TEST: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + probiotic in buccal sachet to be consumed once a day until the quarterly check-up.
POSITIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + industrial placebo in buccal sachet to be consumed once a day until the quarterly check-up.
NEGATIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste.
The products (test and placebo) will be delivered to the patient at the end of the session in order to cover 3 months of administration.
T1 - AFTER 3 MONTHS FROM T0
* Recording of periodontal indices.
* Microbiological samples.
Randomization The treatment that is due to the individual patient is kept in sequentially numbered, opaque and sealed envelopes (SNOSE Sequentially Numbered, Opaque, Sealed Envelopes). The products used for both the test and the controls will be supplied in anonymous tubes so that neither the patient nor the investigator will be aware of them.
Statistical analysis Proper statistical analysiswill be perfomed by the trusted statistical group.
The present study aims to evaluate whether the quarterly oral administration of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 can improve the response to non-surgical periodontal therapy of subgingival instrumentation in patients suffering from stage II-III periodontitis and complexity of grade A-B.
Primary objective To evaluate the adjuvant effect of probiotics based on Lactobacillus plantarum LP14 and Lactobacillus rhamnosus LR04 in non-surgical periodontal therapy.
Secondary objective Characterize the microbiological picture of patients with periodontitis with and without the aid of probiotics.
MATERIALS AND METHODS Three groups of volunteers of both sexes will be enrolled for the study without age restrictions.
Inclusion criteria Patients in the absence of other systemic pathologies reported in the medical history, smokers and non-smokers, non-drinkers, in the absence of previous or current administration of other sources of probiotics, capable of providing informed consent.
Exclusion criteria Subjects with a history of systemic diseases (diabetes, autoimmune diseases, inflammatory bowel diseases, neurodegenerative diseases), drinkers, who take or have taken probiotics in the last 3 months, unable to provide informed consent.
Minimum sample size Sample size calculation (Alpha = 0.05; Power = 95%) for 3 independent study groups, and a continuous primary endpoint. Sample size = Z2 (1-alpha/2) p (1-p) / d2 Where Z(1-alpha/2) is the standard variate corresponding to 1.96 at 5% type 1 error, p is the expected proportion in the population expressed in decimals based on previous studies and d is the confidence level decided by the researcher expressed in decimal. Regarding the primary outcome of Bleeding On Probing (BOP), the expected difference between the means was assumed to be 20%, therefore 20 patients per group are required, for a total of 60 patients. To these patients, the dropout percentage of 10% must be added, so the total is 70 patients.
T0 - BASELINE The first dental visit and the treatment plan will be carried out by Prof. Marco Dolci. The periodontal visit with the registration of the indices and the full-rx will be carried out by Prof. Marco Dolci.
Clinical indixes
* Bleeding On Probing - BOP, percentage value on 6 sites for each tooth
* Pocket Probing Depth - PPD on 6 sites for each tooth
* Clinical Attachment Loss - CAL on intraoral radiographs of pathological sites
* Plaque Index - PI, rated from 0 to 4 for each site
* Percentage of pathological sites out of total sites. The recording of BOP, PPD, PI will be carried out through periodontal probing using the PCP-15 UNC periodontal probe (HuFriedi) in a completely atraumatic and non-invasive manner.
The operational session will be organized as follows:
* Supragingival instrumentation with piezoelectric ultrasonic scaler handpiece;
* BPA microbiological test (Bacterial Periodontal Assessment - Biomolecular Diagnostic, Via Nicola Porpora, 550144 - Florence) through sampling of the gingival crevicular fluid with a thin cone of sterile paper with a diameter of 0.3 mm positioned in the pocket for 60 seconds, in an atraumatic and non-traumatic manner invasive. After sampling, the cones will be inserted into a single test tube;
* Subgingival instrumentation of periodontal pockets using Gracey curettes. The treatment is to be considered as Full Mouth Treatment (FMT). The samples will be transported to the laboratory located on the third floor of Building A, taken into custody by Prof. Marco Dolci and stored at + 4° C until the arrival of the dedicated courier.
The same Biomolecular Diagnostic company will take care of collecting the samples via dedicated biological courier and will carry out the PCR analyzes in its laboratories.
At the end of the analyses, a copy of a unique identification code will be sent to the Experimenters so that they can access the report.
Placement of the patient in the test, positive and negative control groups
TEST: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + probiotic in buccal sachet to be consumed once a day until the quarterly check-up.
POSITIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste + industrial placebo in buccal sachet to be consumed once a day until the quarterly check-up.
NEGATIVE CONTROL: home oral hygiene 2/day with soft bristle toothbrush + standard fluoride toothpaste.
The products (test and placebo) will be delivered to the patient at the end of the session in order to cover 3 months of administration.
T1 - AFTER 3 MONTHS FROM T0
* Recording of periodontal indices.
* Microbiological samples.
Randomization The treatment that is due to the individual patient is kept in sequentially numbered, opaque and sealed envelopes (SNOSE Sequentially Numbered, Opaque, Sealed Envelopes). The products used for both the test and the controls will be supplied in anonymous tubes so that neither the patient nor the investigator will be aware of them.
Statistical analysis Proper statistical analysiswill be perfomed by the trusted statistical group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Periodontitis
Probiotics
Non Surgical Periodontal Therapy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotics
Patients who will be assigned to oral consumption of one stick of probiotics with L. plantarum and L. rhamnosus for 30 days, in adjucntion to routinary oral hygiene procedures.
Group Type
EXPERIMENTAL
Experimental
Intervention Type
OTHER
Orally administred probiotics with L. plantarum and L. rhamnosus
Positive Control
Patients who will be assigned to oral consumption of one stick of placebo for 30 days, in adjucntion to routinary oral hygiene procedures.
Group Type
PLACEBO_COMPARATOR
Positive control
Intervention Type
OTHER
Orally administred placebo without probiotics
Negative control
Patients who will be assigned to routinary oral hygiene procedures esclusively.
Group Type
OTHER
Negative control
Intervention Type
OTHER
Only routinary oral hygiene procedures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Experimental
Orally administred probiotics with L. plantarum and L. rhamnosus
Intervention Type
OTHER
Negative control
Only routinary oral hygiene procedures
Intervention Type
OTHER
Positive control
Orally administred placebo without probiotics
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Orally administration of probiotics with L. plantarum and L. rhamnosus
Only routinary oral hygiene procedures
Orally administred placebo without probiotics
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients in the absence of other systemic pathologies reported in the medical history
* smokers and non-smokers, non-drinkers,
* subjects in the absence of previous or current administration of other sources of probiotics,
* subjects capable of providing informed consent.
* smokers and non-smokers, non-drinkers,
* subjects in the absence of previous or current administration of other sources of probiotics,
* subjects capable of providing informed consent.
Exclusion Criteria
* Subjects with a history of systemic diseases (diabetes, autoimmune diseases, inflammatory bowel diseases, neurodegenerative diseases),
* drinkers,
* subjects who take or have taken probiotics in the last 3 months,
* subjects unable to provide informed consent.
* drinkers,
* subjects who take or have taken probiotics in the last 3 months,
* subjects unable to provide informed consent.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Probiotical S.p.A.
INDUSTRY
Sponsor Role
collaborator
G. d'Annunzio University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Marco Dolci
Full Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marco Dolci, MD DDS PHD
Role: PRINCIPAL_INVESTIGATOR
University G. d'Annunzio of Chieti
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University G. d'Annunzio
Chieti, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Iwasaki K, Maeda K, Hidaka K, Nemoto K, Hirose Y, Deguchi S. Daily Intake of Heat-killed Lactobacillus plantarum L-137 Decreases the Probing Depth in Patients Undergoing Supportive Periodontal Therapy. Oral Health Prev Dent. 2016;14(3):207-14. doi: 10.3290/j.ohpd.a36099.
Reference Type
BACKGROUND
Sulijaya B, Takahashi N, Yamazaki K. Lactobacillus-Derived Bioactive Metabolites for the Regulation of Periodontal Health: Evidences to Clinical Setting. Molecules. 2020 Apr 29;25(9):2088. doi: 10.3390/molecules25092088.
Reference Type
BACKGROUND
Etebarian A, Sheshpari T, Kabir K, Sadeghi H, Moradi A, Hafedi A. Oral Lactobacillus species and their probiotic capabilities in patients with periodontitis and periodontally healthy individuals. Clin Exp Dent Res. 2023 Oct;9(5):746-756. doi: 10.1002/cre2.740. Epub 2023 Apr 20.
Reference Type
BACKGROUND
Pudgar P, Povsic K, Cuk K, Seme K, Petelin M, Gaspersic R. Probiotic strains of Lactobacillus brevis and Lactobacillus plantarum as adjunct to non-surgical periodontal therapy: 3-month results of a randomized controlled clinical trial. Clin Oral Investig. 2021 Mar;25(3):1411-1422. doi: 10.1007/s00784-020-03449-4. Epub 2020 Jul 14.
Reference Type
BACKGROUND
Mendi A, Kose S, Uckan D, Akca G, Yilmaz D, Aral L, Gultekin SE, Eroglu T, Kilic E, Uckan S. Lactobacillus rhamnosus could inhibit Porphyromonas gingivalis derived CXCL8 attenuation. J Appl Oral Sci. 2016 Jan-Feb;24(1):67-75. doi: 10.1590/1678-775720150145.
Reference Type
BACKGROUND
Gatej SM, Marino V, Bright R, Fitzsimmons TR, Gully N, Zilm P, Gibson RJ, Edwards S, Bartold PM. Probiotic Lactobacillus rhamnosus GG prevents alveolar bone loss in a mouse model of experimental periodontitis. J Clin Periodontol. 2018 Feb;45(2):204-212. doi: 10.1111/jcpe.12838. Epub 2017 Dec 11.
Reference Type
BACKGROUND
Morales A, Carvajal P, Silva N, Hernandez M, Godoy C, Rodriguez G, Cabello R, Garcia-Sesnich J, Hoare A, Diaz PI, Gamonal J. Clinical Effects of Lactobacillus rhamnosus in Non-Surgical Treatment of Chronic Periodontitis: A Randomized Placebo-Controlled Trial With 1-Year Follow-Up. J Periodontol. 2016 Aug;87(8):944-52. doi: 10.1902/jop.2016.150665. Epub 2016 Mar 4.
Reference Type
BACKGROUND
Fu J, Jia L, Wu L, Jiang Y, Zhao R, Du J, Guo L, Zhang C, Xu J, Liu Y. Lactobacillus rhamnosus inhibits osteoclast differentiation by suppressing the TLR2/NF-kappaB pathway. Oral Dis. 2024 May;30(4):2373-2386. doi: 10.1111/odi.14712. Epub 2023 Aug 21.
Reference Type
BACKGROUND
Routier A, Blaizot A, Agossa K, Dubar M. What do we know about the mechanisms of action of probiotics on factors involved in the pathogenesis of periodontitis? A scoping review of in vitro studies. Arch Oral Biol. 2021 Sep;129:105196. doi: 10.1016/j.archoralbio.2021.105196. Epub 2021 Jun 10.
Reference Type
BACKGROUND
Nguyen T, Brody H, Radaic A, Kapila Y. Probiotics for periodontal health-Current molecular findings. Periodontol 2000. 2021 Oct;87(1):254-267. doi: 10.1111/prd.12382.
Reference Type
BACKGROUND
Morales A, Gandolfo A, Bravo J, Carvajal P, Silva N, Godoy C, Garcia-Sesnich J, Hoare A, Diaz P, Gamonal J. Microbiological and clinical effects of probiotics and antibiotics on nonsurgical treatment of chronic periodontitis: a randomized placebo- controlled trial with 9-month follow-up. J Appl Oral Sci. 2018 Jan 18;26:e20170075. doi: 10.1590/1678-7757-2017-0075.
Reference Type
BACKGROUND
Teughels W, Durukan A, Ozcelik O, Pauwels M, Quirynen M, Haytac MC. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol. 2013 Nov;40(11):1025-35. doi: 10.1111/jcpe.12155. Epub 2013 Sep 15.
Reference Type
BACKGROUND
Furlaneto F, Ishikawa KH, Messora MR, Mayer MPA. Probiotics During the Therapeutic Management of Periodontitis. Adv Exp Med Biol. 2022;1373:353-375. doi: 10.1007/978-3-030-96881-6_19.
Reference Type
BACKGROUND
Gruner D, Paris S, Schwendicke F. Probiotics for managing caries and periodontitis: Systematic review and meta-analysis. J Dent. 2016 May;48:16-25. doi: 10.1016/j.jdent.2016.03.002. Epub 2016 Mar 8.
Reference Type
BACKGROUND
Lee Y, Yoon Y, Choi KH. Probiotics-Mediated Bioconversion and Periodontitis. Food Sci Anim Resour. 2021 Nov;41(6):905-922. doi: 10.5851/kosfa.2021.e57. Epub 2021 Nov 1.
Reference Type
BACKGROUND
Bustamante M, Oomah BD, Mosi-Roa Y, Rubilar M, Burgos-Diaz C. Probiotics as an Adjunct Therapy for the Treatment of Halitosis, Dental Caries and Periodontitis. Probiotics Antimicrob Proteins. 2020 Jun;12(2):325-334. doi: 10.1007/s12602-019-9521-4.
Reference Type
BACKGROUND
Sanz M, Ceriello A, Buysschaert M, Chapple I, Demmer RT, Graziani F, Herrera D, Jepsen S, Lione L, Madianos P, Mathur M, Montanya E, Shapira L, Tonetti M, Vegh D. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International diabetes Federation and the European Federation of Periodontology. Diabetes Res Clin Pract. 2018 Mar;137:231-241. doi: 10.1016/j.diabres.2017.12.001. Epub 2017 Dec 5.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.efp.org/fileadmin/uploads/efp/Documents/Campaigns/New_Classification/Guidance_Notes/report-02.pdf
New Classification of periodontal and peri-implant diseases
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PARO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Probiotics And Ozonated Olive Oil To Maintain Oral Eubiosis In Stage I And II Periodontitis Patients
NCT06955546
COMPLETED
NA
Efficacy of Supplementation With Probiotics as Adjuvant to Mechanical Treatment in Chronic Periodontitis
NCT03554187
COMPLETED
NA
Probiotics as Adjunct to Nonsurgical Periodontal Treatment
NCT04137419
COMPLETED
NA
Effect of Probiotics as Supplement to Non-surgical Periodontal Treatment
NCT05518747
UNKNOWN
NA
The Use of Chlorhexidine and a Probiotic Lozenge in the Nonsurgical Therapy of Periodontitis
NCT05548361
COMPLETED
NA
Probiotics as Adjunct to Non Surgical Periodontal Therapy for Pregnant Women Oral Health
NCT05400538
COMPLETED
NA
Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy
NCT02520375
WITHDRAWN
NA
Clinical Effects of Limosilactobacillus Reuteri Probiotics as an Adjunct to the Treatment of Periodontitis
NCT05734274
RECRUITING
NA
Impact of Oral Probiotics on Oral Homeostasis
NCT04071210
COMPLETED
NA
A Clinical Trial to Evaluate the Effectiveness of Lactobacillus Reuteri for Periodontitis in a Chinese Population
NCT04129684
UNKNOWN
NA
Effect of Probiotic Lozenge on Gingivitis and Periodontitis
NCT02203812
COMPLETED
PHASE3
Clinical Effect of Lactobacillus Reuteri in Treatment of Gingivitis
NCT02801773
UNKNOWN
PHASE2
Adjunctive Periodontal Treatment With Coenzyme Q10 in Association With Probiotics for Pregnant Women
NCT06308497
ENROLLING_BY_INVITATION
NA
Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers
NCT02329353
COMPLETED
PHASE3
Evaluation of the Effect of a Probiotic in Patients Undergoing Orthodontic Therapy
NCT06752330
COMPLETED
NA
Evaluation of the Effects of Probiotic Toothpastes on Periodontal Health
NCT06514664
ENROLLING_BY_INVITATION
NA
Clinical and Microbiological Effects of Lactobacillus Rhamnosus in Treatment of Gingivitis
NCT02809313
UNKNOWN
PHASE2
Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients
NCT02390687
COMPLETED
PHASE3
Non Surgical Therapy of Periodontitis in Diabetes Patients: the Adjunctive Use of Probiotics
NCT04069611
UNKNOWN
NA
Effect of Probiotic on the Plaque pH. A Randomized Double Blind Interventional Study
NCT01601145
COMPLETED
PHASE4
Anaysis of Phytotherapy Agent Against Periodontitis
NCT04349878
COMPLETED
NA
Systemic Probiotics in the Periodontal Treatment
NCT03733379
UNKNOWN
PHASE3
Effect of Probiotics on Periodontitis Stage III Grade C Molar-incisor Pattern
NCT06253988
COMPLETED
PHASE3
Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection
NCT01438333
COMPLETED
NA
Effects of Probiotics on Oral Health
NCT02444182
COMPLETED
PHASE1/PHASE2